Close menu

news|financial Logo
 

Interview with Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. CEO David Elsley on new therapies for acute myocarditis and recurrent pericarditis

  • Biotechnology
Photo credits: pixabay.com

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

time to read: 1 minutes | The interview was conducted by Mario Hose on January 30th, 2024 in Oakville, Ontario (CAN).

David Elsley, CEO, Cardiol Therapeutics Inc.

David Elsley
CEO | Cardiol Therapeutics Inc.
2265 Upper Middle Road East, 602, L6H 0G5 Oakville, Ontario (CAN)
info@cardiolrx.com

+1 (289) 910-0850

Table of contents:

    COVID and Heart disease

    news|financial: "Heart disease is one of the leading causes of death globally and with the increased awareness brought upon it from the COVID disease and vaccines, do you think it is receiving the recognition it deserves?"

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    The COVID-19 pandemic has underscored the importance of addressing underlying health conditions, such as cardiovascular diseases, and catalyzed efforts to prioritize heart health on a broader scale. As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide.

    Share price trend

    news|financial: "Cardiol shares have been on an upward trend for several months with the positive news announcements, which should please investors. What upcoming milestones and opportunities can investors expect in the near future?"

    We look forward to building off last year’s momentum and completing full enrollment in both our ground-breaking heart disease Phase 2 clinical trials in recurrent pericarditis (MAvERIC-Pilot) and acute myocarditis (ARCHER).

    Phase 2 trials

    news|financial: "What significance does the successful completion of the Phase 2 trials have for people that suffer from the two areas of application?"

    Results of the MAvERIC-Pilot study will help understand the therapeutic profile of our lead investigational drug, CardiolRx™, in recurrent pericarditis, and support the design of a pivotal Phase 3 clinical trial to underpin the potential regulatory approval of CardiolRx™. Likewise, the data generated from patients who enroll in ARCHER will provide important information in support of the use of CardiolRx™ as a novel small molecule therapeutic approach for this debilitating rare disease.

    Market situation

    news|financial: "How does your competitive situation look and what conclusions can investors draw from this?"

    We believe there is a significant opportunity to develop important new therapies for acute myocarditis and recurrent pericarditis, both of which would be eligible for designation as an orphan drug in the United States and the European Union. Orphan drug designation programs provide significant incentives, including periods of prolonged marketing exclusivity and exemptions from certain fees.

    news|financial: "Thank you very much for talking to us."

    • Biotechnology

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.